Schaeffer's Top Stock Picks for '25

Analyst Upgrades: Facebook, Cyberark Software, bluebird bio

Analysts upwardly revised their ratings on Facebook Inc (FB), Cyberark Software Ltd (CYBR), and bluebird bio Inc (BLUE)

Mar 23, 2015 at 9:25 AM
facebook X logo linkedin


Analysts are weighing in today on social network giant Facebook Inc (NASDAQ:FB), cybersecurity firm Cyberark Software Ltd (NASDAQ:CYBR), and drugmaker bluebird bio Inc (NASDAQ:BLUE). Here's a quick roundup of today's bullish brokerage notes on FB, CYBR, and BLUE.

  • It's been a record-setting run for FB of late, and the equity looks ready to extend this momentum today, after receiving price-target hikes from JMP Securities (by $3 to $97) and Piper Jaffray (by $8 to $92) -- both in territory yet to be charted. Longer term, shares of FB are up roughly 25% year-over-year, and closed Friday at $83.80. Options traders, meanwhile, have shown a distinct preference for calls over puts in recent months. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), Facebook Inc's 50-day call/put volume ratio of 2.57 ranks in the 90th annual percentile.

  • CYBR is 3.8% higher in electronic trading, thanks to an upbeat "buy" initiation from BofA-Merrill Lynch, and $60 price target -- representing expected upside of 23.2% to Friday's settlement at $48.69. This optimism shouldn't be too surprising, considering the stock has tacked on almost 23% year-to-date, but isn't shared throughout the brokerage bunch. Specifically, five out of seven analysts maintain a "hold" or worse recommendation on Cyberark Software Ltd, while the average 12-month price target of $46.88 stands at a discount to current trading levels.

  • BLUE has put in a tremendous showing on the charts, surging nearly fivefold over the past 52 weeks to trade at $124.76. Roth Capital thinks there's more room to run, and upped its price target on the stock to $145 from $120 -- in record-high waters. Elsewhere on the Street, however, skepticism has been growing. At the ISE, CBOE, and PHLX, BLUE's 10-day put/call volume ratio of 1.94 indicates nearly two puts have been bought to open for every call over the last two weeks. Plus, short interest jumped 10.9% in the last two reporting periods, and now accounts for a healthy 7.7% of the stock's available float. In fact, it would take more than a week to cover these shorted shares, at average daily trading levels. Should bluebird bio Inc continue its upward trajectory, a capitulation of some of the weaker bearish hands could translate into a fresh burst of buying power for BLUE.
 
 

You have the chance to join one of Bernie's most exclusive programs, complete access at HUGE savings!

As we prepare for a new administration to take the reins in Washington, the near-term market landscape is rife with uncertainty.

The Federal Reserve has already hinted at the turbulence ahead, lowering its interest rate outlook for 2025.

Meanwhile, breakthroughs in artificial intelligence (AI), quantum computing, and other transformative sectors have unlocked incredible profit potential.

But these opportunities are fleeting, and timing is everything. That's where Quick-Hit Trader comes in.

Quick-Hit Trader is designed for precision and speed, getting you in and out of the market in a flash. While other investors scramble to navigate volatile conditions, you'll have access to expertly curated trades that leverage these rapid shifts to deliver explosive profits in short order.

This is your chance to capitalize on the fast-moving market like never before. Are you ready to make your move?